Ute Schellenberger

Ute Schellenberger

Auto-generated profile, based on publicly available information

Ute Schellenberger

Teneobio, Inc., Menlo Park, CA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2019 in mAbs
Verified
Journal Article
Open access
NTNathan D. Trinklein
Nathan D. Trinklein
DPDuy Pham
Duy Pham
USUte Schellenberger
Ute Schellenberger
BBBen Buelow
Ben Buelow
ABAndrew Boudreau
Andrew Boudreau
SAShelley Force Aldred
Shelley Force Aldred
T-cell-recruiting bispecific antibodies (T-BsAbs) have shown potent tumor killing activity in humans, but cytokine release-related toxicities have affected their clinical utility. The use of novel anti-CD3 binding domains with more favorable properties could aid in the creation of T-BsAbs with improved therapeutic windows. Using a sequence-based discovery platform, we identified new anti-CD3 antibodies from humanized rats that bind to multiple epitopes and elicit varying levels of T-cell activation. In T-BsAb format, 12 different anti-CD3 arms induce equivalent levels of tumor cell lysis by primary T-cells, but potency varies by a thousand-fold. Our lead CD3-targeting arm stimulates very low levels of cytokine release, but drives robust tumor antigen-specific killing in vitro and in a mouse xenograft model. This new CD3-targeting antibody underpins a next-generation T-BsAb platform in which potent cytotoxicity is uncoupled from high levels of cytokine release, which may lead to a wider therapeutic window in the clinic.

1 January 2021 in mAbs
Verified
Journal Article
Open access
HMHarbani K. Malik-Chaudhry
Harbani K. Malik-Chaudhry
KPKirthana Prabhakar
Kirthana Prabhakar
HUHarshad S. Ugamraj
Harshad S. Ugamraj
ABAndrew A. Boudreau
Andrew A. Boudreau
BBBenjamin Buelow
Benjamin Buelow
URUdaya S. Rangaswamy
Udaya S. Rangaswamy
The therapeutic potential of targeting CD19 in B cell malignancies has garnered attention in the past decade, resulting in the introduction of novel immunotherapy agents. Encouraging clinical data have been reported for T cell-based targeting agents, such as anti-CD19/CD3 bispecific T-cell engager blinatumomab and chimeric antigen receptor (CAR)-T therapies, for acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma (B-NHL). However, clinical use of both blinatumomab and CAR-T therapies has been limited due to unfavorable pharmacokinetics (PK), significant toxicity associated with cytokine release syndrome and neurotoxicity, and manufacturing challenges. We present here a fully human CD19xCD3 bispecific antibody (TNB-486) for the treatment of B-NHL that could address the limitations of the current approved treatments. In the presence of CD19+ target cells and T cells, TNB-486 induces tumor cell lysis with minimal cytokine release, when compared to a positive control. In vivo, TNB-486 clears CD19+ tumor cells in immunocompromised mice in the presence of human peripheral blood mononuclear cells in multiple models. Additionally, the PK of TNB-486 in mice or cynomolgus monkeys is similar to conventional antibodies. This new T cell engaging bispecific antibody targeting CD19 represents a novel therapeutic that induces potent T cell-mediated tumor-cell cytotoxicity uncoupled from high levels of cytokine release, making it an attractive candidate for B-NHL therapy.

20 August 2022 in OncoImmunology
Verified
Journal Article
Open access
BABrian C. Avanzino
Brian C. Avanzino
KPKirthana Prabhakar
Kirthana Prabhakar
PDPranjali Dalvi
Pranjali Dalvi
SHSharon Hartstein
Sharon Hartstein
HKHannes Kehm
Hannes Kehm
KHKatherine E. Harris
Katherine E. Harris
The use of T-cell engagers (TCEs) to treat solid tumors is challenging, and several have been limited by narrow therapeutic windows due to substantial on-target, off-tumor toxicities due to the expression of low levels of target antigens on healthy tissues. Here, we describe TNB-928B, a fully human TCE that has a bivalent binding arm for folate receptor alpha (FRα) to selectively target FRα overexpressing tumor cells while avoiding the lysis of cells with low levels of FRα expression. The bivalent design of the FRα binding arm confers tumor selectivity due to low-affinity but high-avidity binding to high FRα antigen density cells. TNB-928B induces preferential effector T-cell activation, proliferation, and selective cytotoxic activity on high FRα expressing cells while sparing low FRα expressing cells. In addition, TNB-928B induces minimal cytokine release compared to a positive control TCE containing OKT3. Moreover, TNB-928B exhibits substantial ex vivo tumor cell lysis using endogenous T-cells and robust tumor clearance in vivo, promoting T-cell infiltration and antitumor activity in mouse models of ovarian cancer. TNB-928B exhibits pharmacokinetics similar to conventional antibodies, which are projected to enable favorable administration in humans. TNB-928B is a novel TCE with enhanced safety and specificity for the treatment of ovarian cancer.

26 September 1998 in Biochemistry
Verified
Journal Article
Closed access
TSThomas J. Stout
Thomas J. Stout
USUte Schellenberger
Ute Schellenberger
DSDaniel V Santi
Daniel V Santi
RSRobert M. Stroud
Robert M. Stroud

1 November 1995 in European Journal of Cancer
Verified
Journal Article
Closed access
PDF file
PSPatrick Schöffski
Patrick Schöffski
CKC.-H. Köhne
C.-H. Köhne
USU. Schellenberger
U. Schellenberger
USU. Schubert
U. Schubert
HWH. Wilke
H. Wilke
Hans Joachim SchmollHans Joachim Schmoll
Hans Joachim Schmoll

1 March 2019 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SCStarlynn Clarke
Starlynn Clarke
KDKevin Dang
Kevin Dang
YLYuping Li
Yuping Li
PSPreethi Sankaran
Preethi Sankaran
DPDuy Pham
Duy Pham
BBBen Buelow
Ben Buelow
324 Background: Castration resistant prostate cancer (CRPC) remains an incurable disease and new therapeutics are urgently needed. Prostate specific membrane antigen (PSMA) is expressed on the surface of prostate cancer cells and expression increases with disease progression. Therapies directed against PSMA such as radiolabeled antibodies and T cell redirecting therapies including chimeric antigen receptor T cells (CAR-Ts) and T-cell engaging bispecific antibodies (T-BsAbs) have shown promising efficacy in clinical trials but also induce significant toxicity. In particular CAR-Ts and T-BsAbs potently kill tumor cells but induce cytokine release-related toxicities. Novel anti-CD3 engaging domains may be required to create T-BsAbs with a broader therapeutic window. We have developed fully human CD3xPSMA bispecific antibodies that efficiently eliminate prostate tumor cells while minimizing cytokine release. Methods: Antibodies targeting CD3 and PSMA were generated in transgenic rats that produce human antibodies (UniRat, OmniFlic) followed by repertoire deep sequencing of lymph nodes isolated from immunized animals and high-throughput gene assembly/expression. CD3xPSMA T-BsAbs were assembled and evaluated for T cell activation and ability to eliminate PSMA+ tumor cells in vitro. Results: Primary human T cells were activated only in the presence of both bispecific CD3xPSMA antibodies and PSMA (either plate-bound or on the surface of tumor cells). Potent and selective cytotoxicity against PSMA+ prostate tumor cells was observed in co-cultures of primary human T cells and tumor cells treated with CD3xPSMA bispecific antibodies. Strikingly, CD3xPSMA bispecifics containing a novel low affinity anti-CD3 domain produced similar levels of tumor cell cytotoxicity compared to CD3xPSMA bispecifics containing a traditional high affinity anti-CD3 domain, but with reduced cytokine production. Conclusions: We have created novel CD3xPSMA bispecific antibodies that mediate T-cell killing of PSMA+ tumor cells with minimal production of cytokines. Such T-BsAbs may improve safety, efficacy, and opportunities for combination therapy to treat CRPC.